Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
Shi‐Wei Huang, Chih‐Ming Pan, Yu‐Chuan Lin, et al.
Advanced Science (2023) Vol. 10, Iss. 17
Open Access | Times Cited: 23

Showing 23 citing articles:

Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions
Peilin Lu, Dongxue Ruan, Meiqi Huang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 65
Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy
Megan Yuan, Wenjun Wang, Isobel Hawes, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies
Christina Angeliki Tsiverioti, Adrian Gottschlich, Marcel P. Trefny, et al.
Biological Chemistry (2024) Vol. 405, Iss. 7-8, pp. 485-515
Open Access | Times Cited: 8
CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy
Jiawen Huang, Qian Yang, Wen Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations
Beatriz Martín-Antonio, Belén Blanco, África González‐Murillo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Targeting Dual Immune Checkpoints PD‐L1 and HLA‐G by Trispecific T Cell Engager for Treating Heterogeneous Lung Cancer
Yu‐Chuan Lin, Mei‐Chih Chen, Shi‐Wei Huang, et al.
Advanced Science (2024) Vol. 11, Iss. 41
Open Access | Times Cited: 5
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Human γδ T cells in the tumor microenvironment: Key insights for advancing cancer immunotherapy
Won Hyung Park, Heung Kyu Lee
Molecules and Cells (2025), pp. 100177-100177
Open Access
Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment
H. In, Minkyoung Park, H.-K. Lee, et al.
Antibodies (2025) Vol. 14, Iss. 1, pp. 16-16
Open Access
γδT cells, a key subset of T cell for cancer immunotherapy
Jianzhen Lv, Zheng Liu, Xingye Ren, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
mRNA‐based chimeric antigen receptor T cell therapy: Basic principles, recent advances and future directions
Kaiting Xiao, Yanming Lai, Wenxu Yuan, et al.
Deleted Journal (2023) Vol. 2, Iss. 1
Open Access | Times Cited: 10
Sulforaphane activates CD8+T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’
Jinyan Liu, Huanan Chen, Caijuan Guo, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007983-e007983
Open Access | Times Cited: 3
mRNA‐Engineered CD5‐CAR‐γδTCD5‐ Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia
Zhixiong Zhu, Hexian Li, Qizhong Lu, et al.
Advanced Science (2024)
Open Access | Times Cited: 3
Potential of gamma/delta T cells for solid tumor immunotherapy
Dantong Zhu, Xijing Ren, Wanting Xie, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Human platelet lysate enhances in vivo activity of CAR-Vδ2 T cells by reducing cellular senescence and apoptosis
Feiyan Mo, Chiou‐Tsun Tsai, Rong Zheng, et al.
Cytotherapy (2024) Vol. 26, Iss. 8, pp. 858-868
Open Access | Times Cited: 1
γδ T cells and the PD-1/PD-L1 axis: a love–hate relationship in the tumor microenvironment
Jian Liu, Min Wu, Yifan Yang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy
C Carcopino, Ergun Erdoğan, M Henrich, et al.
Immuno-Oncology Technology (2024) Vol. 24, pp. 100739-100739
Open Access | Times Cited: 1
Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma
Kun Ma, Ping Hu
Cancers (2023) Vol. 15, Iss. 23, pp. 5652-5652
Open Access | Times Cited: 3
A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells
Zhifeng Yan, Runxia Gu, Nianci Chen, et al.
Research Square (Research Square) (2024)
Open Access
A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells
Zhifeng Yan, Runxia Gu, Haotian Ma, et al.
Cellular Oncology (2024) Vol. 47, Iss. 5, pp. 1879-1895
Closed Access
γδ T cells for cancer immunotherapy: A 2024 comprehensive systematic review of clinical trials
Marta Barisa, Callum Nattress, Daniel H. Fowler, et al.
Elsevier eBooks (2024), pp. 103-153
Closed Access
CAR-armored-cell therapy in solid tumor treatment
Yan Liu, Lin Xiao, Man Yang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Page 1

Scroll to top